HKU Scholars Hub: Browsing DSpace

Browsing by Author Hurwitz, H

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 12 of 12

	Title	Author(s)	Issue Date	Views
	Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial Proceeding/Conference:Journal of Clinical Oncology	Liu, Y Clarke, J Starr, MD Brady, JC Pang, HMH Rushing, C Alvarez, D Adams, BJ Theuer, CP Hurwitz, H Nixon, AB	2014	46
	Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance) Proceeding/Conference:Journal of Clinical Oncology	Clarke, JM Pang, HMH Starr, MD Hatch, AJ Kindler, HL O'Reilly, EM Innocenti, F Venook, AP Hurwitz, H Nixon, AB	2015	42
	Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors Proceeding/Conference:Journal of Clinical Oncology	Strickler, JH McCall, S Nixon, AB Pang, HMH Rushing, C Arrowood, C Haley, S Meadows, K Hurwitz, H	2013	41
	Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing Journal:Clinical Cancer Research	Jia, J Dellinger, A Weiss, E Bulusu, A Rushing, C Li, H Howard, L Kaplan, N Pang, HMH Hurwitz, H	2015	48
	Direct Evidence of Targeted Inhibition by Anti-angiogenic Agents from a Wound-healing Model in Patients with Advance Solid Tumors Proceeding/Conference:Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy Conference	Jia, J Dellinger, A Weiss, ES Bulusu, A Li, H Howard, L Kaplan, N Pang, HMH Hurwitz, H Nixon, AB	2014	36
	A leave-one-out cross-validation SAS macro for the identification of markers associated with survival Journal:Computers in Biology and Medicine	Rushing, C Bulusu, A Hurwitz, H Nixon, A Pang, HMH	2015	63
	Modulation of angiogenic biomarkers in patients receiving high-dose TRC105 Proceeding/Conference:Journal of Clinical Oncology	Liu, Y Starr, M Brady, JC Pang, HMH Dellinger, A Leigh, BR Theuer, CP Hurwitz, H Nixon, AB	2012	35
	Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors Proceeding/Conference:Journal of Clinical Oncology	Liu, Y Starr, M Pang, HMH Marcello, J Leigh, BR Theuer, CP Hurwitz, H Nixon, AB	2011	59
	Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors Proceeding/Conference:Journal of Clinical Oncology	Jia, J Li, H Dellinger, A Pang, HMH Russell, KB Hurwitz, H Nixon, AB	2012	43
	Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303 Proceeding/Conference:Journal of Clinical Oncology	Nixon, AB Pang, HMH Starr, M Hollis, D Friedman, PN Bertagnolli, MM Kindler, HL Goldberg, RM Venook, AP Hurwitz, H	2011	44
	Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance) Proceeding/Conference:Journal of Clinical Oncology	Hatch, AJ Pang, HMH Starr, MD Brady, JC Jia, J Chen, J Sibley, A Owzar, K Niedzwiecki, D Venook, AP Cushman, SM Hurwitz, H Nixon, AB	2014	36
	Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A) Proceeding/Conference:Journal of Clinical Oncology	Nixon, A Starr, M Pang, HMH Bulusu, A Honeycutt, W Amara, A Bendell, JC Hurwitz, H	2010	48

Showing results 1 to 12 of 12